Melatonin, Neuroprotective Agents and Antidepressant Therapy

1. Chronobiology of Mood Disorders

   • Felice Iasevoli, Livia Avvisati, Valentina Gilardi, Gianmarco Latte, Emiliano Prinzivalli, Domenico de Berardis et al.

   Pages 273-295

2. Bipolar Disorders and Biological Rhythms

   • Robert Gonzalez

   Pages 297-317

3. Circadian Clock Genes and Mood Disorders

   • Timo Partonen

   Pages 319-334

4. Understanding the Biologically Adaptive Side of Mood Disorders: A Focus on Affective Temperaments

   • Xenia Gonda, Gustavo H. Vazquez

   Pages 335-346

5. Sleep Abnormalities as a Diagnostic Tool for Major Depressive Disorder

   • Alan B. Douglass, Marcus Ward, Timothy Roerhrs, Cynthia L. Arfken, Nash N. Boutrous

   Pages 347-356

6. Depression: Correlations with Thyroid Hormones in Major Depressive Disorder

   • Dominika Berent

   Pages 357-363

7. History of the Discovery of Antidepressant Drugs

   • Francisco López-Muñoz, Cecilio Álamo

   Pages 365-383

8. Neurocognitive Deficit in Bipolar Disorders

   • Dimos Dimelis, Xenia Gonda, Konstantinos N. Fountoulakis

   Pages 385-420

9. Combination Strategies in Treatment-Resistant Depression

   • Francisco López-Muñoz, Cecilio Álamo, Pilar García-García

   Pages 421-444

10. Antidepressant Drugs in Elderly

    • Cecilio Álamo, Francisco López-Muñoz, Pilar García-García

    Pages 445-463

11. Antidepressant Efficacy of Escitalopram in Major Depressive Disorder

    • Eiji Kirino

    Pages 465-476

12. Antidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?

    • Gianluca Serafini, Paola Solano, Mario Amore

    Pages 477-499

13. Neurobiology and Pharmacological Prevention of Suicide in Mood Disorders

    • Xenia Gonda, Zoltan Rihmer, Peter Dome

    Pages 501-522

14. Antidepressant and Anticonvulsant Drugs as Adjuvant Analgesics in Chronic Pain

    • Manuel Sebastián-Aldeanueva, Francisco López-Muñoz, José Antonio Guerra, Cecilio Álamo

    Pages 523-532

15. Genetic Polymorphisms of Cytochrome P450 and Antidepressants

    • Ana Isabel Wu-Chou, Yu-Li Liu, Winston W. Shen

    Pages 533-543

16. Pharmacogenomics of Antidepressant Drugs

    • Ramón Cacabelos, Clara Torrellas, Francisco López-Muñoz

    Pages 545-609

17. Antidepressants Modulate Microglia Beyond the Neurotransmitters Doctrine of Mood Disorders

    • Masahiro Ohgidani, Takahiro A. Kato, Yoshito Mizoguchi, Hideki Horikawa, Akira Monji, Shigenobu Kanba

    Pages 611-620

18. Brain-Derived Neurotrophic Factor (BDNF): TrkB Signaling in Depression – Biomarker and Novel Therapeutic Target

    • Kenji Hashimoto

    Pages 621-629

19. Targeting Opioid Receptors for Innovative Antidepressant Therapies: Rediscovering the Opioid Cure

    • Emmanuel Darcq, Paul Chu-Sin-Chung, Brigitte L. Kieffer, Pierre-Eric Lutz

    Pages 631-653

20. Prolactin and Somatostatin Responses to Antidepressant Therapy

    • Agata Faron-Górecka, Kinga Szafran-Pilch

    Pages 655-666

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities   in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. .

• Agomelatine
• Chronobiology of mood disorders
• Hippocampal neurogenesis, depression and antidepressants
• Melatonergic drugs in sleep and depressive disorders
• Melatonin and mood disorders
• psychopharmacology

• Vice-Rectorate for Research and Sci, Camilo José Cela University Vice-Rectorate for Research and Sci, Madrid, Spain

  Francisco López-Muñoz

• International Medical Sciences Research Study Center, Sri Sathya Sai Medical Educational & Research Foundation, Coimbatore, India

  Venkataramanujam Srinivasan

• Department of Neurosciences and Ima, University of Chieti Department of Neurosciences and Ima, Italy, Italy

  Domenico de Berardis

• Department of Biomedical Sciences (Pharmacology Area), University of Alcalá, Madrid, Spain

  Cecilio Álamo

• Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan

  Takahiro A. Kato

Prof.Venkataramanujan Srinivasan,Msc, Ph.D MAMS SRI SATHYA SAI MEDICAL EDUCATIONAL AND RESEARCH FOUNDATION An International Medical Sciences Research Study Center “PrasanthiNilayam”, KOVAI, Coimbatore, Tamilnadu, INDIA

Policies and ethics